



DOSSIER · SUBSTANCE

Huperzine A

Research on **Huperzine A** is broad, but unevenly distributed: the majority of the studies originate from basic laboratory work and animal experiments. In humans, controlled testing is almost entirely focused on **Alzheimer dementia** and **vascular dementia**; for healthy users, a dedicated controlled study is still pending.

389

STUDIES IN
TOTAL

69

IN HUMANS

23

OF WHICH
CONTROLLED

114

IN ANIMALS

35

IN THE LAB

Figures from the IHR study database · Last updated 2026-10-15

How to Read This Dossier

ESTABLISHED

measured in humans, with a comparison group

PLAUSIBLE

supported by mechanism, animal studies or observation

HYPOTHESIS

a likely connection that still needs to be tested

Huperzine A at a Glance

ORIGIN:

Huperzine A is an alkaloid from the group of Lycopodium alkaloids. It occurs in Huperzia species used in Chinese herbal medicine tradition. As an acetylcholinesterase inhibitor, it blocks the enzyme that breaks down the neurotransmitter acetylcholine; review articles classify it in the same drug class as the synthetic cholinesterase inhibitors used in dementia.

EVIDENCE BASE:

389 evaluated papers · 23 controlled human studies · 46 observational studies · 24 review articles · 114 animal studies · 34 cell-culture studies

STRONGEST EVIDENCE:

- Alzheimer's dementia: Several meta-analyses of randomised trials exist for Alzheimer's dementia, including one review with 1,823 participants (1) and another with 733 participants (2).
- Vascular dementia: A dedicated meta-analysis and individual controlled studies address this group; the number of papers is lower than for Alzheimer's dementia (2, 11).
- Safety and tolerability: A separate block of controlled studies records safety endpoints; no serious adverse events were reported in controlled human studies (51, 52, 57).
- Cognition after neurosurgery: A randomised clinical trial with 2,023 participants reports improved early postoperative cognitive function after general anaesthesia (5).
- Absorption and availability: Controlled human studies examine pharmacokinetics, tolerability and bioavailability of oral dosage forms in fasted healthy men (14, 40).

LIMITATIONS:

- Healthy users: Controlled human testing is almost entirely focused on Alzheimer's dementia and vascular dementia; a dedicated trial in healthy individuals is still pending.
- Formulation: The meta-analyses pool tablets, capsules and other forms, so the statement applies to the tested Huperzine A formulations and not to a single preparation.
- Long-term: Safety studies cover limited time periods; whether tolerability is maintained with longer use is an open, testable question.

CLASSIFICATION:

An alkaloid from Huperzia species whose controlled human testing has so far been directed at Alzheimer's dementia and vascular dementia.

1. What Huperzine A Is

Huperzine A is an **alkaloid** from the group of **Lycopodium alkaloids**. The substance belongs to the **acetylcholinesterase inhibitors**: it blocks the enzyme that breaks down the neurotransmitter acetylcholine. Review articles place it in the same drug class as the synthetic cholinesterase inhibitors used in dementia. The literature also describes **neuroprotective** and **antioxidative** properties that have so far been investigated mainly in cell and animal models. Some of the papers address the immune effects of cholinesterase inhibitors in general and not of Huperzine A alone.

For the evaluation of all studies, **absorption** of the substance is decisive. Huperzine A is tested in different **dosage forms** — as tablet, as capsule, and in newer preclinical work also **intranasally** via nanoparticle carriers. **Bioavailability** is a separate research strand with its own controlled human studies. Anyone comparing results is therefore not comparing the same thing: the tested preparations, the uptake into the body and the measurement of blood levels differ between the studies. Some of the literature also examines the substance not as a medicinal product but as a **lead structure** for the synthesis of new inhibitors. Statements about effects in humans can therefore be related only to the specific preparation tested.

2. How Reliable the Research Is

The literature on Huperzine A spans several levels. The largest share consists of **basic-science** and **animal-experiment** papers; cell-culture studies and mechanistic reviews are also included. In humans, both **observational** and **controlled** studies exist. Among the controlled studies, the field of **cognition** dominates by a wide margin; a second focus lies on **safety** and tolerability. Further controlled studies address **bioavailability** and antioxidant questions. Individual papers touch on the gut, the musculoskeletal system and oncology. Clinical testing is therefore clearly directed at **dementia** — Alzheimer's dementia and vascular dementia — while other areas of application have been investigated only sporadically.

Methodologically the field rests on two pillars. **Proven**: Several meta-analyses of randomised trials exist for Alzheimer's dementia and one further for vascular dementia; they belong to the most-cited clinical papers in the field. On the other hand, the individual studies are often small. The **safety data** rest on a dedicated group of controlled studies, which is noteworthy for a plant alkaloid. The preclinical base is broad: mechanism, animal and cell culture are well covered. What remains open is testing outside dementia and independent replication of the clinical findings.

Distribution of **controlled human studies** by area of application — the figures are not additive because one paper may be assigned to several areas:

AREA OF APPLICATION	CONTROLLED STUDIES
Cognition and psyche	20
Safety and tolerability	15

AREA OF APPLICATION	CONTROLLED STUDIES
Absorption and availability	3
Oxidative stress	2
Gut and microbiome	1
Musculoskeletal system	1
Oncology	1

What is being tested is a dementia treatment, not a cognition enhancer for healthy people

The controlled human studies test Huperzine A almost exclusively in people with

ALZHEIMER'S DEMENTIA

or **vascular dementia**. The titles of the papers consistently name these two groups. For **healthy** users expecting cognitive performance enhancement, a dedicated controlled trial is still pending. **Plausible**: In dementia a disturbed neurotransmitter balance is influenced; in healthy individuals this point of attack is absent. Anyone classifying Huperzine A as a **nootropic** relies on an evidence base that has not examined this question.

A second point concerns the

FORMULATION

. The clinical studies test tablets, capsules and other forms; absorption of the substance differs between them. The meta-analyses pool these different forms, which limits the statement about any single preparation. **Hypothesis**: Differences between the preparations contribute to the dispersion of results. In addition there is the issue of **combination**: one study compares cholinesterase inhibitors in combination with another active substance, so the effect of Huperzine A cannot be isolated within it. The most robust statement therefore concerns the tested drug class and the tested patient group, not a single preparation.

3. What Is Frequently Claimed — and What the Data Provide

STATEMENT	STUDY SITUATION
Cognitive performance enhancement in healthy users	The controlled studies examine people with dementia. For healthy individuals, a dedicated examination is still pending; the question is open and has not been a
Alzheimer's dementia	Several meta-analyses of randomised studies and individual controlled trials are available. They pool different preparations; the results are not transferable to a
Vascular dementia	A dedicated meta-analysis and individual controlled studies address this group. The number of studies is lower here than for Alzheimer's dementia.
Tolerability and safety	Ein eigener Block kontrollierter Studien erhebt Sicherheitsendpunkte. This is a strength of the field; long-term data beyond the tested periods are still outstandi

4. Profile: Molecule and Charge

Huperzine A is not a single molecule, but a **mixture** — there is no empirical formula and no fixed molecular mass. What can be described are functional groups, charge behaviour and redox properties; this is precisely what the next section addresses.

5. Charge, Electrons, Radicals

Regarding charge, the material provides two measurements on carrier systems: HupA-Lf-TMC nanoparticles showed a zeta potential of +35.6±5.2 mV, HupA-NE of -4.48±0.97 mV ^{26 29}. Both values arise at the particle surface, not at the active substance itself. For the substance itself, the interaction of its primary amine group with carboxyl end groups of PLG polymers as counterion is described ²⁵; a high molecular weight of the polymer affects release unfavourably due to the lower number of such end groups ²⁵. In humans, nothing has been measured regarding the charge of the substance itself.

Regarding radical formation, a controlled human study is available: changes in oxygen radicals improved in both groups, and pathological changes in oxygen radicals were reduced in plasma and erythrocytes of patients with Alzheimer's dementia ^{23 24}. Preclinically, huperzine A dose-dependently lowered Abeta25-35-induced ROS formation in rat cortical neurons ^{27 27} and prevented the increase in reactive oxygen species at the mitochondrion ^{28 30}; ROS formation was likewise reduced in cell culture ³¹. It remains open which oxygen radicals were captured and whether the finding can be replicated in humans.

6. Interactions with Other Substances

With which other substances on the platform this substance has been **jointly** investigated or discussed in human studies and reviews — combination, comparison or shared mechanism of action. The number indicates works in which both occur.

SUBSTANCE	JOINT WORKS	OF WHICH CONTROLLED IN HUMANS
Acceptance and Commitment Therapy (ACT)	54	13
Cognitive Behavioural Therapy for Insomnia (CBT-I)	38	14
Chronic inflammation	13	0
Stress, cortisol and inflammation	9	0
Ginkgo biloba	8	1
Art therapy	8	2
Turmeric and curcumin	6	0
Adaptogens	6	0
Resveratrol	5	0
Myofascial release	5	0

Regarding the absorption of huperzine A, a controlled human study compared two formulations with an established reference formulation; pharmacokinetics, tolerability and bioavailability were tested in fasted, healthy men ¹⁴. Intake therefore occurred without food. For an implantable dosage form, a prolonged treatment duration, less frequent dosing and increased bioavailability of huperzine A are described ³⁴; these advantages are described, not measured in a controlled trial. Whether CYP enzymes, transport proteins such as P-glycoprotein or nutrients alter absorption would need to be examined specifically.

A controlled human study compared four cholinesterase inhibitors together with memantine in Alzheimer patients; the combined use of memantine and cholinesterase inhibitors showed improved outcomes ³². Whether huperzine A was among the four inhibitors tested would need to be clarified in the original publication. Extracts from *Huperzia serrata* act as cholinesterase inhibitors and as antagonists of the glutamic acid receptor ³³. Plausible: Concurrent administration of huperzine A and glutamatergically active medicinal products affects the same transmission pathway; whether the effects are potentiated or attenuated could only be clarified in a study that tests both together.

7. Overdosage, Tolerability, Limits

Safety assessments in animals and humans showed no unexpected toxicity ⁽⁷⁾. Neuroprotective findings against organophosphate poisoning and against glutamate-induced cell death derive from animal studies and are therefore to be classified as preclinical ⁽⁷⁾. A reliable upper limit has yet to be established; information on contraindications is not found in the cited works.

In controlled human studies no serious adverse events were reported ^(1, 35, 8). In 3 % of patients treated with huperzine alpha, mild and transient events occurred: bilateral ankle oedema and insomnia ⁽³⁶⁾. A comparative study of capsule and tablet forms found no serious adverse effects in either group apart from mild to moderate nausea ⁽²⁴⁾. In people with cocaine use disorder, huperzine A was safe and well tolerated ⁽¹⁵⁾. The cited statements do not specify doses. What remains to be clarified is which dose remains safe over longer periods and how tolerability is affected in impaired liver or kidney function.

8. The Most Robust Studies

Ordered by strength of evidence, not by familiarity: systematic reviews and studies with large numbers of participants first. The complete evaluation comprises considerably more works; the most robust ones are presented here.

Controlled Studies in Humans

- ¹ Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials (2013) — Systematic review, 1,823 participants
- ² Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis (2014) — Systematic review, 733 participants
- ³ Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis (2009) — Systematic review
- ⁴ [Efficacy and safety of huperzine A in treating patients with mild cognitive impairment: a systematic review and Meta-analysis] (2019) — Systematic review
- ⁵ Huperzine A associated with improved early postoperative cognitive function after neurosurgery under general anesthesia: a randomized clinical trial (2025) — 2,023 participants

- ⁶ Huperzine A for Alzheimer's disease (2008) — 454 participants
- ⁷ The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of ... (2003)
- ⁸ Treatment with Huperzine A improves cognition in vascular dementia patients (2012) — 78 participants
- ⁹ An update on huperzine A as a treatment for Alzheimer's disease (2008)
- ¹⁰ Role of huperzine a in the treatment of Alzheimer's disease (2009)
- ¹¹ Huperzine A for vascular dementia (2009) — 14 participants
- ¹² Identification of the optimal cognitive drugs among Alzheimer's disease: a Bayesian meta-analytic review (2018)
- ¹³ Huperzine A for the treatment of cognitive, mood, and functional deficits after moderate and severe TBI (HUP-TBI): results of a Phase II randomized ... (2020)
- ¹⁴ Pharmacokinetics and tolerability of oral dosage forms of huperzine a in healthy Chinese male volunteers: a randomized, single dose, three-period ... (2017)
- ¹⁵ Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use Disorder (2015) — 14 participants
- ¹⁶ Population pharmacokinetic modeling and simulation of huperzine A in elderly Chinese subjects (2016)
- ¹⁷ Huperzine A (2004)

Observational Studies in Humans

- ¹⁸ The effects of Huperzine A on dementia and mild cognitive impairment: An overview of systematic reviews (2021) — Overview
- The Lycopodium alkaloids (2004)
- ¹⁹ Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine (2006)
- ²⁰ Huperzine A from Huperzia species--an ethnopharmacological review (2007)
- ²¹ Plant alkaloids as drug leads for Alzheimer's disease (2015)
- ²² Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease (2000)
- Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet Syndrome (2015)

9. Summary

Proven is the dementia indication: several meta-analyses of randomised studies exist for Alzheimer's dementia, and one further for vascular dementia; they rank among the most cited clinical works in the field. The overview with 1,823 participants and the one with 733 participants stand at the forefront. Added to this is a separate block of controlled studies on safety and tolerability in which no serious adverse events were reported; this is noteworthy for a plant alkaloid. The tested preparations differ, however, and the meta-analyses pool them: the most robust statement concerns the tested active-substance class and the tested patient group, not an individual preparation. For healthy users a separate controlled examination is still pending.

Plausible is that the effect connects to the disturbed neurotransmitter balance of a dementia: there a disturbed acetylcholine balance is influenced; in healthy individuals this point of attack is absent. It is also plausible that simultaneous administration with glutamatergically active medicines touches the same transmission pathway; whether the effects reinforce or attenuate each other could be clarified only in a study that tests both together. **Hypothesis:** The differences between the tested preparations contribute to the dispersion of the results, and the antioxidant findings in humans could be examined with a defined preparation and defined measurement of oxygen radicals.

A randomised study in healthy people would clarify whether huperzine A alters cognitive performance in the absence of dementia. A study with a defined preparation and measured blood levels would establish comparability of the clinical works; whether CYP enzymes, transport proteins such as P-glycoprotein or nutrients alter uptake would need targeted examination. Also open is which dose remains safe over longer periods, how tolerability fares with impaired liver or kidney function, and whether the findings on oxygen radicals can be reproduced. At the original work it would need to be clarified whether huperzine A was counted among the four cholinesterase inhibitors tested together with memantine.

10. What Remains Open

- **Healthy users:** whether huperzine A alters cognitive performance in people without dementia has so far been examined in no controlled study. A randomised study in healthy individuals would clarify this question.
- **Uniform preparation:** the clinical works test different dosage forms. A study with a defined preparation and measured blood levels would establish comparability.
- **Long-term course:** the safety studies cover limited time spans. Whether tolerability is maintained over longer use is an open, testable question.

11. Further Paths

Topics, mechanisms of action and chains in which this substance occurs — for all who wish to look beyond the substance.

- Wechselwirkungsnetz

Frequently Asked Questions

Which dosage form has been studied for use in humans?

Tablets and capsules have been tested, among others; one study directly compares both forms. In preclinical studies, an intranasal administration via nanoparticle carriers is additionally investigated, but not yet in humans. Bioavailability is the subject of separate controlled studies. Therefore, for the assessment, it is important which preparation a study actually used.

How does Huperzine A differ from synthetic cholinesterase inhibitors?

Huperzine A belongs, like these, to the group of **acetylcholinesterase inhibitors**, but is a **natural alkaloid** from Huperzia species. One study compares several cholinesterase inhibitors in combination with another active substance in Alzheimer dementia. A direct, isolated comparison of the substances against each other is not included. Classification as a plant-derived inhibitor says nothing about the magnitude of an effect.

What should be considered when evaluating the meta-analyses?

The meta-analyses pool randomised studies on **Alzheimer dementia** and **vascular dementia**. They combine studies with different preparations, dosages and observation periods. This increases the number of evaluated participants, but also averages out the differences between the studies. A statement about an individual preparation cannot be derived from this.

Sources

- 1 Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
Yang G, Wang Y, Tian J, Liu JP · 2013
- 2 Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis
Xing SH, Zhu CX, Zhang R, An L · 2014
- 3 Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis
Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ · 2009
- 4 [Efficacy and safety of huperzine A in treating patients with mild cognitive impairment: a systematic review and Meta-analysis]
Huang P, Li B, Guo YH, Feng S, Hu J, Liu QQ · 2019
- 5 Huperzine A associated with improved early postoperative cognitive function after neurosurgery under general anesthesia: a randomized clinical trial
Zhang Z, Shen Y, Li J, Tang Y, Zhou P, Ying T et al. · 2025
- 6 Huperzine A for Alzheimer's disease
Li J, Wu HM, Zhou RL, Liu GJ, Dong BR · 2008
- 7 The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease
Zangara A · 2003
- 8 Treatment with Huperzine A improves cognition in vascular dementia patients
Xu ZQ, Liang XM, Juan-Wu, Zhang YF, Zhu CX, Jiang XJ · 2012
- 9 An update on huperzine A as a treatment for Alzheimer's disease
Little JT, Walsh S, Aisen PS · 2008
- 10 Role of huperzine a in the treatment of Alzheimer's disease
Desilets AR, Gickas JJ, Dunican KC · 2009
- 11 Huperzine A for vascular dementia
Hao Z, Liu M, Liu Z, Lv D · 2009
- 12 Identification of the optimal cognitive drugs among Alzheimer's disease: a Bayesian meta-analytic review
Liang J, Li J, Jia R, Wang Y, Wu R, Zhang H et al. · 2018
- 13 Huperzine A for the treatment of cognitive, mood, and functional deficits after moderate and severe TBI (HUP-TBI): results of a Phase II randomized controlled pilot study: implications for understanding the placebo effect
Zafonte RD, Fregni F, Bergin MJG, Goldstein R, Boudreau N, Monge I et al. · 2020
- 14 Pharmacokinetics and tolerability of oral dosage forms of huperzine a in healthy Chinese male volunteers: a randomized, single dose, three-period, six-sequence crossover study
Wu SL, Gan J, Rao J, He SJ, Zhu WW, Zhao Y et al. · 2017
- 15 Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use Disorder
De La Garza R, Verrico CD, Newton TF, Mahoney JJ, Thompson-Lake DG · 2015
- 16 Population pharmacokinetic modeling and simulation of huperzine A in elderly Chinese subjects
Sheng L, Qu Y, Yan J, Liu GY, Wang WL, Wang YJ et al. · 2016
- 17 Huperzine A
· 2004
- 18 The effects of Huperzine A on dementia and mild cognitive impairment: An overview of systematic reviews
Ghassab-Abdollahi N, Mobasser K, Dehghani Ahmadabad A, Nadrian H, Mirghafourvand M · 2021
- 19 Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine
Wang R, Yan H, Tang XC · 2006
- 20 Huperzine A from Huperzia species--an ethnopharmacological review
Ma X, Tan C, Zhu D, Gang DR, Xiao P · 2007
- 21 Plant alkaloids as drug leads for Alzheimer's disease
Ng YP, Or TC, Ip NY · 2015
- 22 Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease
Bai DL, Tang XC, He XC · 2000
- 23 The changes of oxygen free radicals in 2 groups showed marked improvement....
· 1999
- 24 No severe side effect besides moderate to mild nausea was found in both groups. Conclusion There is equal efficac...
· 1999
- 25 Counter-ionic interaction between the primary amine group of Huperzine A and the carboxylic terminal group of PLG polyme...
· 2005
- 26 The biodistribution of Hup-A NPs after intranasal administration was determined by liquid chromatography-tandem mass spe...
· 2018
- 27 Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reac...
· 2002
- 28 In addition to inhibiting the Abeta(25-35) (40 microM)-induced decrease in mitochondrial respiration, adenosine 5'-triph...
· 2009
- 29 A drug targeting index (DTI) was calculated to determine brain-targeting efficiency. Results Optimized HupA-NE ha...
· 2019
- 30 Moreover, huperzine A treatment rescued mitochondrial dysfunction induced by oligomeric Aβ(42), including adenosine trip...
· 2015
- 31 HupA and derivatives significantly suppressed the Aβ25-35 cytotoxicity and showed recovery effects against ar...
· 2025
- 32 Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer...
· 2015
- 33 Extracts from Huperzia serrata (HS) function as a cholinesterase inhibitor and a glutamic acid receptor antagonist....
· 2018
- 34 When used to cure senile diseases such as alzheimer disease and vascular dementia, The implantable dosage has the advant...
· 2008
- 35 No severe side effect was found. Conclusion Hup is a promising drug for symptomatic treatment of Alzheimer's dise...
· 1995
- 36 Mild and transient adverse events (edema of bilateral ankles and insomnia) were observed in 3% of huperzine Alpha treat...
· 2002

International Health Research

Research, put in context. Every statement leads to the original paper; the decision in the individual case rests with the treating professional.
ih-research.com/en/knowledge/huperzine-a/ · Last updated 2026-10-15